<?xml version="1.0" encoding="UTF-8"?>
<funding-group>
 <award-group id="award001">
  <funding-source>
   <institution>Bill and Melinda Gates Foundation</institution>
  </funding-source>
  <award-id>OPP1017716</award-id>
  <principal-award-recipient>
   <name>
    <surname>Murphy</surname>
    <given-names>Gary</given-names>
   </name>
  </principal-award-recipient>
 </award-group>
 <award-group id="award002">
  <funding-source>
   <institution>Bill and Melinda Gates Foundation</institution>
  </funding-source>
  <award-id>OPP1062806</award-id>
  <principal-award-recipient>
   <name>
    <surname>Pilcher</surname>
    <given-names>Christopher D.</given-names>
   </name>
  </principal-award-recipient>
 </award-group>
 <award-group id="award003">
  <funding-source>
   <institution>Bill and Melinda Gates Foundation</institution>
  </funding-source>
  <award-id>OPP1115799</award-id>
 </award-group>
 <award-group id="award004">
  <funding-source>
   <institution>National Institute of Health (NIH)</institution>
  </funding-source>
  <award-id>R34 MH096606</award-id>
  <principal-award-recipient>
   <name>
    <surname>Pilcher</surname>
    <given-names>Christopher D.</given-names>
   </name>
  </principal-award-recipient>
 </award-group>
 <funding-statement>The Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA) was supported by grants from the Bill and Melinda Gates Foundation (OPP1017716 to G.M., OPP1062806 to C.D.P. and OPP1115799). Additional support for analysis was provided by a grant from the US National Institutes of Health (R34 MH096606 to C.D.P.) and by the South African Department of Science and Technology and the National Research Foundation. Specimen and data collection were funded in part by grants from the NIH (P01 AI071713, R01 HD074511, P30 AI027763, R24 AI067039, U01 AI043638, P01 AI074621 and R24 AI106039); the HIV Prevention Trials Network (HPTN) sponsored by the NIAID, National Institutes of Child Health and Human Development (NICH/HD), National Institute on Drug Abuse, National Institute of Mental Health, and Office of AIDS Research, of the NIH, DHHS (UM1 AI068613 and R01 AI095068); the California HIV-1 Research Program (RN07-SD-702); Brazilian Program for STD and AIDS, Ministry of Health (914/BRA/3014-UNESCO); and the São Paulo City Health Department (2004-0.168.922– 7). Selected samples from International AIDS Vaccine Initiative (IAVI)-supported cohorts were funded by IAVI with the generous support of USAID and other donors; a full list of IAVI donors is available at 
  <ext-link ext-link-type="uri" xlink:href="http://www.iavi.org" xmlns:xlink="http://www.w3.org/1999/xlink">www.iavi.org</ext-link>. S.N.F. is affiliated to Facente Consulting. Facente Consulting provided support in the form of salary for author S.N.F. but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the ‘author contributions’ section. N.P. is Executive Director of Data First Consulting, Inc., which received salary support for this project from the Bill and Melinda Gates Foundation through grant OPP1115799 to FIND (Geneva, Switzerland). The funder did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the ‘author contributions’ section. The funders provided support in the form of salaries for authors J.B.S., A.W., M.P.B., J.H., D.H., S.M.K., K.M., C.D.P., G.M. and E.G. but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.
 </funding-statement>
</funding-group>
